Anecortave

Anecortave
Clinical data
Pregnancy; category	?;
Routes of; administration	intravitreal depot injection
ATC code	S01XA16 (WHO) ;
Legal status
Legal status	Schedule 4 (Aust);
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Elimination half-life	?
Excretion	?
Identifiers
	IUPAC name [2-[(8R,10S,13S,14R,17R)-; 17-hydroxy-10,13-dimethyl-3-oxo-; 2,6,7,8,12,14,15,16-octahydro-; 1H-cyclopenta[a]phenanthren-17-yl]-; 2-oxo-ethyl] acetate;
CAS Number	7753-60-8;
PubChem CID	111332;
DrugBank	?;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C23H30O5
Molar mass	386.48

Anecortave (rINN) (Template:PronEng) is a novel angiogenesis inhibitor used in the treatment of the exudative (wet) form of age-related macular degeneration. Although based on a steroid nucleus, it possesses little glucocorticoid activity. It is marketed by Alcon as anecortave acetate for depot suspension under the trade name Retaane.

External links

Clinical data
Pregnancy category	?
Routes of administration	intravitreal depot injection
ATC code	S01XA16 (WHO)
Legal status
Legal status	Schedule 4 (Aust)
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Elimination half-life	?
Excretion	?
Identifiers
IUPAC name [2-[(8R,10S,13S,14R,17R)- 17-hydroxy-10,13-dimethyl-3-oxo- 2,6,7,8,12,14,15,16-octahydro- 1H-cyclopenta[a]phenanthren-17-yl]- 2-oxo-ethyl] acetate
CAS Number	7753-60-8
PubChem CID	111332
DrugBank	?
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₂₃H₃₀O₅
Molar mass	386.48